Now that Chimerix has had to scrap its Phase III program for brincidofovir, the biotech has slashed its workforce by 20% as it regroups around smaller studies with more than $300 million in the bank.
Durham, NC-based Chimerix had 131 staffers at the end of December, according to its 10-K, implying that it handed out pink slips to 26 workers.
Investigators for the biotech fingered a set of side effects triggering the use of corticosteroids for the failure of its lead late-stage study for the antiviral, focused on reducing the rate of cytomegalovirus infection. The study also demonstrated a spike in the deaths of patients in the drug arm compared to the placebo group. Now Chimerix is shifting focus to a preclinical IV formulation that the biotech believes can be used without the troublesome corticosteroids. In the meantime, the biotech is cutting costs to conserve the $343 million in cash that it had in the bank at the end of 2015.
“In light of the SUPPRESS results, in early 2016 we completed an approximate 20 percent reduction in our workforce,” says Tim Trost, the CFO of Chimerix, in a statement. “We expect our research and corporate expenses to trend downward this year prior to discussions with regulators and agreement on further clinical development requirements. Once that path forward has been set, we would expect to provide more granular expense guidance.”
Chimerix posted a loss of $117.4 million in 2015, leaving it with enough capital to continue to fund a pared-down operation for three years.
Brincidofovir–which is the company’s sole focus–is a lipid-conjugated version of cidofovir specifically designed to amp up the antiviral impact with a pill while sparing kidneys from a toxic threat. Its ability to get into cells more effectively than cidofovir has been touted as a far more effective counterpunch to 5 DNA viral infections. In a small open-label pilot study driven by the compassionate-use case of young Josh Hardy, the antiviral was successful in dramatically reducing the rate of adenovirus infections.
By John Carroll
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
